Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 14/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AOC2 | O75106 | 3/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988807 | 0.79 | GABRA1 (0.46) | CYP3A4MET | |
| SCHEMBL25237063 | 0.74 | NOS2 (0.56) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL5988224 | 0.69 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL2827343 | 0.68 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL11796135 | 0.67 | AOC2 (0.66) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL29068210 | 0.66 | NPC1 (0.35) | CYP1A2CYP3A4MET | |
| SCHEMBL2495046 | 0.65 | MEN1 (0.55) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL14424070 | 0.65 | MEN1 (0.38) | CYP2C9MET | |
| SCHEMBL968125 | 0.63 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9AOC3AOC2 | |
| SCHEMBL2222457 | 0.63 | NNMT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CYP1A2 966/4885CYP3A4 894/4885CYP2C9 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.